Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
The master cytokine TGF-β mediates tissue fibrosis associated with inflammation and tissue injury. TGF-β induces fibroblast activation and differentiation into myofibroblasts that secrete extracellular matrix proteins. Canonical TGF-β signaling mobilizes Smad2 and Smad3 transcription factors that control fibrosis by promoting gene expression. However, the importance of TGF-β-Smad2/3 signaling in fibroblast-mediated cardiac fibrosis has not been directly evaluated in vivo. Here, we examined pressure overload-induced cardiac fibrosis in fibroblast- and myofibroblast-specific inducible Cre-expressing mouse lines with selective deletion of the TGF-β receptors Tgfbr1/2, Smad2, or Smad3. Fibroblast-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced the pressure overload-induced fibrotic response as well as fibrosis mediated by a heart-specific, latency-resistant TGF-β mutant transgene. Interestingly, cardiac fibroblast-specific deletion of Tgfbr1/2, but not Smad2/3, attenuated the cardiac hypertrophic response to pressure overload stimulation. Mechanistically, loss of Smad2/3 from tissue-resident fibroblasts attenuated injury-induced cellular expansion within the heart and the expression of fibrosis-mediating genes. Deletion of Smad2/3 or Tgfbr1/2 from cardiac fibroblasts similarly inhibited the gene program for fibrosis and extracellular matrix remodeling, although deletion of Tgfbr1/2 uniquely altered expression of an array of regulatory genes involved in cardiomyocyte homeostasis and disease compensation. These findings implicate TGF-β-Smad2/3 signaling in activated tissue-resident cardiac fibroblasts as principal mediators of the fibrotic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overexpression of SMAD3 enhances, whereas knockdown inhibits αSMA and extracellular matrix production in fibroblasts (45–48). Furthermore, fibroblast-specific deletion of SMAD3 reduces αSMA production and myofibroblast phenotype (49–52), for example, loss of SMAD3 lowers the number of activated myofibroblasts in cardiac fibrosis in vivo and reduces extracellular matrix production by myofibroblasts”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“By contrast, cultured human primary cardiac and dermal fibroblasts and immortalized cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ (refs. 19,39,40), IL-1β (ref. 41)) conditions.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“TGF-β1 activates SMAD2/3 signaling, driving pro-fibrotic gene expression and extracellular matrix deposition in cardiac fibroblasts [85].”
From A Paradigm Shift: Arrhythmogenic Cardiomyopathy Is an Inflammatory Disease (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, primary human cardiac fibroblasts, primary human dermal fibroblasts, and immortalized human cardiac fibroblasts were relatively poor models of human cardiac fibroblast diversity under resting or stimulated (TGFβ 20,33,34 , IL-1 β 35 ) conditions.”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“While numerous studies have implicated a role for TGFβ signaling in maladaptive cardiac remodeling and scar formation in HF 20,33”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [33]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591 · cited 1×
“Heart failure is an increasingly prevalent disease characterized by reduced cardiac output resulting from a progressive loss of cardiomyocytes, ventricular chamber remodeling, and accumulation of interstitial fibrosis (1).”
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2016.01.011 · Cited by 5,262
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528 · cited 1×
“Global TGF-β activity is upregulated in diseased hearts, where one of its primary actions is directed at the resident fibroblasts to alter the fibrotic response and ventricular remodeling (47, 48).”
Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., et al. (2016) · European Heart Journal – Cardiovascular Imaging · doi:10.1093/ehjci/jew082 · Cited by 2,425 · cited 1×
“The ratio of these measures ( E/e ′ ) was used as an indicator of diastolic function (60).”
Cardiac Fibroblast: The Renaissance Cell
Souders, C. A., Bowers, S. L. K., & Baudino, T. A. (2009) · Circulation Research · doi:10.1161/circresaha.109.209809 · Cited by 984 · cited 1×
“Progressive cardiac fibrosis in heart failure is predominantly mediated by the tissue-resident cardiac fibroblast, which becomes activated and then differentiated into a cell type referred to as the myofibroblast (5, 6).”
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934 · cited 1×
“TGF-β is considered a “master” cytokine/growth factor produced within injured or diseased tissues, where it activates fibroblasts and facilitates ECM production (15, 16).”
The role of TGF-β signaling in myocardial infarction and cardiac remodeling
BUJAK, M., & FRANGOGIANNIS, N. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.10.002 · Cited by 927
Genetic lineage tracing defines myofibroblast origin and function in the injured heart
Kanisicak, O., Khalil, H., Ivey, M. J., Karch, J., Maliken, B. D., Correll, R. N., Brody, M. J., J. Lin, S.-C., Aronow, B. J., Tallquist, M. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12260 · Cited by 892 · cited 6×
“Hence, here we used mice in which the Postn genetic locus was targeted with a tamoxifen-inducible MerCreMer (MCM) cDNA (29), and these mice were crossed with Smad2 fl/fl , Smad3 fl/fl , Smad2/3 fl/fl , and Tgfbr1/2 fl/fl targeted mice (Figure 2A).”
InfluentialSelf-citation
Cited by
Items 201–300 of 925
Diaz, M. D., Tran, E., Spang, M. T., Wang, R. M., Gaetani, R., Luo, C., Braden, R. L., Hill, R. C., Hansen, K. C., DeMaria, A. N., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.01.003 · Cited by 41
Li, J., Ge, F., Wuken, S., Jiao, S., Chen, P., Huang, M., Gao, X., Liu, J., Tu, P., Chai, X., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154078 · Cited by 41
Abo-Saif, M. A., Ragab, A. E., Ibrahim, A. O., Abdelzaher, O. F., Mehanyd, A. B. M., Saber-Ayad, M. M., & El-Feky, O. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1166653 · Cited by 41
“Transforming growth factor-β is the master cytokine that mediates fibrosis in various tissues as a consequence of tissue injury and inflammation (Khalil et al., 2017).”
BackgroundInhibition of HSP90 S‐nitrosylation alleviates cardiac fibrosis via TGFβ/SMAD3 signalling pathway
Zhang, X., Zhang, Y., Qing, M., Shi, Z., Hu, L., Liu, S., Gao, J., Zhao, S., Chen, H., Huang, Z., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15626 · Cited by 41
Tanner, M. A., Thomas, T. P., Maitz, C. A., & Grisanti, L. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228507 · Cited by 46
Smad-dependent pathways in the infarcted and failing heart
Humeres, C. D., Venugopal, H., & Frangogiannis, N. G. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102207 · Cited by 45
Frangogiannis, N. G. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2316735 · Cited by 42
“In experimental models of pressure overload, chronic TGF-β activation was found to play an important role in fibrotic myocardial remodeling and chronic dysfunction (Figure 3) [124].”
BackgroundTargeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis
Yang, B., Qiao, Y., Dong, Y., & Meng, Q. (2024) · Cells · doi:10.3390/cells13090764 · Cited by 42
“Several possible targets for the treatment of cardiac fibrosis have emerged in recent years, including the TGF-β signaling pathway [130,131], fibronectin [59], HMGA1 [132], and BET [133].”
BackgroundWang, B., Cheng, M., Yang, S., Qiu, W., Li, W., Zhou, Y., Wang, X., Yang, M., He, H., Zhu, C., et al. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.122677 · Cited by 39
Garlapati, V. S., Molitor, M., Michna, T., Harms, G. S., Finger, S., Jung, R., Lagrange, J., Efentakis, P., Wild, J., Knorr, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci156436 · Cited by 41
“Disruption of the TF-PAR2 signaling complex on myeloid cells significantly reduces TGF-β1–mediated SMAD2 activation localized to myofibroblasts, which play a crucial role in post-MI remodeling (43, 44), but not to immune cells (28).”
BackgroundCharacterization of a robust mouse model of heart failure with preserved ejection fraction
Matsiukevich, D., Kovács, A. D., Li, T., Kokkonen-Simon, K. M., Matkovich, S. J., Oladipupo, S. S., & Ornitz, D. M. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00038.2023 · Cited by 39
Cell therapy in end-stage liver disease: replace and remodel
Hu, X.-H., Chen, L., Wu, H., Tang, Y.-B., Zheng, Q.-M., Wei, X.-Y., Wei, Q., Huang, Q., Chen, J., & Xu, X. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03370-z · Cited by 32
“Smad2/3 is phosphorylated by the TGF-β signalling pathway, which activates downstream molecules such as extracellular matrix (ECM) genes and causes collagen deposition [54].”
BackgroundInhibitory effect of microRNA-21 on pathways and mechanisms involved in cardiac fibrosis development
Khalaji, A., Mehrtabar, S., Jabraeilipour, A., Doustar, N., Youshanlouei, H. R., Tahavvori, A., Fattahi, P., Alavi, S. M. A., Taha, S. R., Naghibi, A. F., et al. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241253134 · Cited by 38
“48 Conversely, a deficiency in Smad3 may exacerbate the progression of cardiac fibrosis.”
BackgroundCurcumin Management of Myocardial Fibrosis and its Mechanisms of Action: A Review
Yu, Y., Sun, J., Wang, R., Liu, J., Wang, P., & Wang, C. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500861 · Cited by 39
Zhu, X., Shi, D., Cao, K., Ru, D., Ren, J., Rao, Z., Chen, Y., You, Q., Dai, C., Liu, L., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.007 · Cited by 39
Targeting regulatory T cells for cardiovascular diseases
Wang, X., Zhou, H., Liu, Q., Cheng, P., Zhao, T., Yang, T., Zhao, Y., Sha, W., Zhao, Y., & Qu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126761 · Cited by 41
Kong, M., Zhou, J., Kang, A., Kuai, Y., Xu, H., Li, M., Miao, X., Guo, Y., Fan, Z., Xu, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329671 · Cited by 38
Torimoto, K., Elliott, K., Nakayama, Y., Yanagisawa, H., & Eguchi, S. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae044 · Cited by 38
Zhang, H., Zhao, J., Yu, J., Zhang, X., Ran, S., Wang, S., Ye, W., Luo, Z., Li, X., Hao, Y., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1489438 · Cited by 39
Maliken, B. D., Kanisicak, O., Karch, J. M., Khalil, H., Fu, X., Boyer, J. G., Prasad, V., Zheng, Y., & Molkentin, J. D. (2018) · Circulation · doi:10.1161/circulationaha.118.033703 · Cited by 43
Self-citationSaw, E. L., Pearson, J. T., Schwenke, D. O., Munasinghe, P. E., Tsuchimochi, H., Rawal, S., Coffey, S., Davis, P. J., Bunton, R. W., van Hout, I., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01231-8 · Cited by 39
“TGF-β1 induces signaling cascade to activate transcription factor Smad2 and Smad3, thus upregulating downstream genes that are involved in myofibroblast differentiation [50, 51].”
BackgroundChen, G., Xu, H., Wu, Y., Han, X., Xie, L., Zhang, G., Liu, B., & Zhou, Y. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153719 · Cited by 38
Torrieri, G., Ferreira, M. P. A., Shahbazi, M., Talman, V., Karhu, S. T., Pohjolainen, L., Carvalho, C., Pinto, J. F., Hirvonen, J. J., Ruskoaho, H. J., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202109032 · Cited by 37
Ronan, G., Bahçecioğlu, G., Yang, J., & Zorlutuna, P. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2024.122671 · Cited by 37
Diamond‐Inspired DNA Hydrogel Based on Tetrahedral Framework Nucleic Acids for Burn Wound Healing
Liu, Z., Chen, X., Xu, Z., Li, S., Ma, W., Wang, Y., Chen, Y., Yao, L., Liang, J., Liao, S., et al. (2025) · Advanced Materials · doi:10.1002/adma.202509727 · Cited by 36
Cardiac fibroblasts in myocardial injury and heart failure
Linthout, S. V., Matz, I., González, A., & Davis, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf902 · Cited by 48
“148,149 153 Endothelial-to-mesenchymal transition can lead to coronary microvascular rarefaction, further exacerbating cardiac fibrosis.”
Yang, S., Yang, G., Wang, X., Xiang, J., Kang, L., & Liang, Z. (2022) · Cell Death and Disease · doi:10.1038/s41419-023-06169-1 · Cited by 39
“Importantly, TGF-β-SMAD2/3 signaling pathway, in addition to its role as a profibrotic factor, is a prohypertrophic factor in the heart [53].”
BackgroundGarvin, A. M., Both, M. D. D., Talboom, J. S., Lindsey, M. L., Huentelman, M. J., & Hale, T. M. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16352 · Cited by 35
“11 The most salient findings were (1) the hypertensive heart of SHRs contains clusters that suggest distinct phenotypes including activated (cluster 1), proliferative (cluster 2), moderately fibrogenic (cluster 3), low fibrogenic (cluster 0); (2) transient ACE inhibitor treatment reduced cardiac fibroblast heterogenei…”
BackgroundFroese, N., Cordero, J., Abouissa, A., Trogisch, F. A., Grein, S., Szaroszyk, M., Wang, Y., Gigina, A., Korf‐Klingebiel, M., Bošnjak, B., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103965 · Cited by 37
“As an example, genes in cluster 1 exerted binding motifs for E2F transcription factors and CHR motifs (known regulate cell cycle genes) and SMAD (known to induce the expression of extracellular matrix genes) (Khalil et al., 2017; Muller et al., 2017).”
BackgroundHan, X., Yang, Y., Zhang, M., Li, L., Xue, Y., Jia, Q., Wang, X., & Guan, S. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s386805 · Cited by 35
“The imbalance of MMP and excessive secretion of cytokines such as TGF-β eventually leads to MF.(54,55) It has been shown that the upregulation of MMPs after MI leads to a reduction in myocardial tissue thickness (thinning of the ventricular wall), which ultimately leads to deterioration of cardiac function.”
BackgroundInfluentialBrassington, K., Kanellakis, P., Cao, A. H., Toh, B., Peter, K., Bobik, A., & Kyaw, T. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1040233 · Cited by 38
“Transforming growth factor-beta1 (TGF-b1) is the most important pro-fibrotic cytokine for development of cardiac fibrosis (8) and exerts its effects by stimulating cardiac fibroblasts to produce collagen (9, 10).”
BackgroundMicroparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice
Tang, L. F. P., Qiu, H., Xu, B., Su, Y., Nyarige, V., Li, P., Chen, H., Killham, B., Liao, J., Adám, H., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.324608 · Cited by 37
“85 The translocation of TGF-β receptors to the nucleus triggers the transcription of Smad2/3.”
Nazari‐Shafti, T. Z., Neuber, S., Duran, A. G., Exarchos, V., Beez, C. M., Meýborg, H., Krüger, K., Wolint, P., Buschmann, J., Böni, R., et al. (2020) · Biomolecules · doi:10.3390/biom10091353 · Cited by 39
“In the context of TGF-beta signaling, SMAD2, 3, and 4 are the downstream promoters that can activate pro-fibrotic gene expression in multiple tissues including the heart [36].”
BackgroundMaione, A. S., Stadiotti, I., Pilato, C. A., Perrucci, G. L., Saverio, V., Catto, V., Vettor, G., Casella, M., Guarino, A., Polvani, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052673 · Cited by 35
Rho Kinases in Embryonic Development and Stem Cell Research
Shi, J., & Wei, L. (2022) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-022-00642-z · Cited by 37
Cardiac Macrophages and Their Effects on Arrhythmogenesis
Xia, R., Tomsits, P., Loy, S., Zhang, Z., Pauly, V., Schüttler, D., & Clauß, S. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.900094 · Cited by 36
Nonmyocytes as electrophysiological contributors to cardiac excitation and conduction
Simón-Chica, A., Wülfers, E. M., & Köhl, P. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00184.2023 · Cited by 36
Controlling cardiac fibrosis through fibroblast state space modulation
Reichardt, I. M., Robeson, K. Z., Regnier, M., & Davis, J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109888 · Cited by 36
Research Progress of Myocardial Fibrosis and Atrial Fibrillation
Li, G., Yang, J., Zhang, D., Wang, X., Han, J., & Guo, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889706 · Cited by 39
Park, H., Hoffman, J. R., Brown, M. E., Bheri, S., Brazhkina, O., Son, Y. H., & Davis, M. E. (2023) · Science Advances · doi:10.1126/sciadv.abo4616 · Cited by 36
Review: Acetylation mechanisms and targeted therapies in cardiac fibrosis
Liu, W., Yuan, Q., Cao, S., Wang, G., Liu, X., Xia, Y., Bian, Y., Xu, F., & Chen, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106815 · Cited by 35
Quijada, P. J., Misra, A., Velasquez, L. S., Burke, R. M., Lighthouse, J. K., Mickelsen, D. M., Dirkx, R. A., & Small, E. M. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.01.015 · Cited by 33
Yu, F., Bao, Y., Ding, J., Li, H., Liu, W., Wang, X., Guan, H., & Chen, Z. (2022) · Bioengineered · doi:10.1080/21655979.2022.2033380 · Cited by 35
“The TGF-β/Smad signaling specific to CFs allegedly underlies cardiac fibrosis [8].”
BackgroundSuppression of NADPH oxidase 4 inhibits PM2.5-induced cardiac fibrosis through ROS-P38 MAPK pathway
Wu, M., Xing, Q., Duan, H., Qin, G., & Sang, N. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155558 · Cited by 33
The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
Fan, J., Ren, M., Adhikari, B. K., Wang, H., & He, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s370483 · Cited by 34
“Current research has revealed a close connection between the well-studied TGF-β/Smad signaling pathway and cardiac fibrosis, affecting both the secretion and degradation of ECM components and myofibroblast differentiation (Figure 1D).(46) In addition, the involvement of the innate immune system in the regulation of he…”
BackgroundWang, M., Wang, M., Zhao, J., Xu, H., Xi, Y., & Yang, H. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154849 · Cited by 34
Duan, F., Barrón, G. M., Meliton, A. Y., Mutlu, G. M., Dulin, N. O., & Schuger, L. A. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0028oc · Cited by 38
Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction
He, W., Chen, P., Chen, Q., Cai, Z., & Zhang, P. (2022) · Inflammation Research · doi:10.1007/s00011-022-01611-0 · Cited by 33
miR-1468-3p Promotes Aging-Related Cardiac Fibrosis
Lin, R., Rahtu‐Korpela, L., Magga, J. M., Ulvila, J., Swan, J., Kemppi, A., Pakanen, L., Porvari, K., Huikuri, H. V., Junttila, J. M., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.001 · Cited by 31
“More recently, both fibroblast-specific TGF-b1 receptor knockout and SMAD3 knockout were shown to attenuate pressure overload-induced cardiac fibrosis.(13) There are two key pathways that mediate TGF-b1 signaling: the canonical SMAD pathway and the non-canonical signaling pathways.”
BackgroundBachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
Ackerman, J. E., Muscat, S. N., Adjei‐Sowah, E., Korcari, A., Nichols, A. E. C., Buckley, M. R., & Loiselle, A. E. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.12.004 · Cited by 37
Diabetes Promotes Myocardial Fibrosis via AMPK/EZH2/PPAR-γ Signaling Pathway
Li, S.-S., Pan, L., Zhang, Z., Zhou, M.-D., Chen, X., Qian, L., Dai, M., Lu, J., Yu, Z.-M., Dang, S., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0031 · Cited by 31
“Myofibroblasts display acerbated proliferative, migratory and contractile abilities with excessive deposition of extracellular matrix (ECM) [5,6].”
BackgroundMultiomic analysis of monocyte-derived alveolar macrophages in idiopathic pulmonary fibrosis
Zhang, M., Zhang, J., Hu, H., Zhou, Y., Lin, Z., Jing, H., & Sun, B. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05398-y · Cited by 34
“SMAD2, a member downstream molecule of the TGFβ pathway, is involved in promoting the expression of MHC molecules and regulating phagocytosis in macrophages and thus could be recognized as a major mediator of fibrosis [53, 54].”
BackgroundStatins in Mitigating Anticancer Treatment-Related Cardiovascular Disease
Jiang, R., Lou, L., Shi, W., Chen, Y., Fu, Z., Liu, S., Sok, T., Li, Z., Zhang, X., & Yang, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810177 · Cited by 34
“This activation prompts fibroblasts to produce the extracellular matrix, which leads to cardiac fibrosis [124].”
BackgroundRole of Cardiac Fibroblasts in Cardiac Injury and Repair
Han, M., & Zhou, B. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01647-y · Cited by 32
Quattrocelli, M., Wintzinger, M., Miz, K., Levine, D. C., Peek, C. B., Bass, J. T., & McNally, E. M. (2022) · Science Advances · doi:10.1126/sciadv.abm1189 · Cited by 34
Zhang, Y., Wang, D., Zhao, Z., Liu, L., Xia, G., Ye, T., Chen, Y., Xu, C., Jin, X., & Shen, C. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.71780 · Cited by 30
“An array of studies have been focused on preserving cardiomyocytes[3, 4], increasing angiogenesis[5], and ameliorating detrimental fibrotic remodelling[6, 7].”
BackgroundLi, Y., Li, C., Liu, Q., Wang, L., Bao, A. X., Jung, J. P., Dodlapati, S., Sun, J., Gao, P., Zhang, X., et al. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.08.003 · Cited by 30
“Gel contraction assay was performed as previously described with some modifications [26].”
MethodSelf-citationBowers, S., Meng, Q., Kuwabara, Y., Huo, J., Minerath, R. A., York, A. J., Sargent, M. A., Prasad, V., Saviola, A. J., Galindo, D. C., et al. (2023) · Cells · doi:10.3390/cells12172174 · Cited by 36
Self-citationRehman, M., Vodret, S., Braga, L., Guarnaccia, C., Celsi, F., Rossetti, G., Martinelli, V. C., Battini, T., Long, C. S., Vukušić, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123987 · Cited by 32
“In particular, transforming growth factor-β (TGF-β) stimulates the migration of fibroblasts and their activation into myofibroblasts (5, 6).”
BackgroundStauffer, W. T., Blackwood, E. A., Azizi, K., Kaufman, R. J., & Glembotski, C. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041373 · Cited by 30
Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts
Martufi, M., Good, R. B., Rapiteanu, R., Schmidt, T., Patili, E., Tvermosegaard, K., New, M. I., Nanthakumar, C. B., Betts, J. C., Blanchard, A. D., et al. (2019) · The CRISPR Journal · doi:10.1089/crispr.2018.0047 · Cited by 32
“In the context of disease, SMAD3, but not SMAD2, appears to be important for mediating TGF-b signaling in renal fibrosis,(30) hepatic fibrosis,(31) and cardiac fibrosis.(32) In contrast, SMAD2 is crucial for epiblast development and patterning of three germ layers during early developmental events.”
BackgroundLi, S., Tu, C., Wan, L., Chen, R., Duan, Z., Ren, X., & Li, Z. (2019) · Cell Division · doi:10.1186/s13008-019-0056-6 · Cited by 32
“In previous studies, it has been found that enhanced TGF-beta expression and strengthened TGF-β signaling resulted in the augmented phosphorylation of Smad2 [21].”
InfluentialTransforming Growth Factor Beta3 is Required for Cardiovascular Development
Chakrabarti, M., Al-Sammarraie, N., Gebere, M. G., Bhattacharya, A., Chopra, S., Johnson, J., Peña, E. A., Eberth, J. F., Poelmann, R. E., Groot, A. C. G., et al. (2020) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd7020019 · Cited by 32
“Several studies have indicated that TGFβ signaling is required for collagen production, remodeling, and organization [35,51,52].”
BackgroundGacita, A. M., Dellefave‐Castillo, L. M., Page, P., Barefield, D. Y., Wasserstrom, J. A., Puckelwartz, M. J., Nóbrega, M. A., & McNally, E. M. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.006926 · Cited by 32
LncRNA-PVT1 activates lung fibroblasts via miR-497-5p and is facilitated by FOXM1
Li, Y., Sun, W., Pan, H., Yuan, J., Xu, Q., Xu, T., Li, P., Cheng, D., Liu, Y., & Ni, C. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112030 · Cited by 35
Elevated IgE promotes cardiac fibrosis by suppressing miR-486a-5p
Zhao, H., Yang, H., Geng, C., Chen, Y., Tang, Y., Li, Z., Pang, J., Shu, T., Nie, Y., Liu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.47845 · Cited by 29
“SMAD2 signaling is widely regarded as one of the principal fibrotic mediators that promotes cardiac fibrosis [32, 56], attributed a crucial role in miR-486a-5p-mediated anti-fibrotic effects in other tissues [27, 33].”
BackgroundThe Potential of Hsp90 in Targeting Pathological Pathways in Cardiac Diseases
Roberts, R. J., Hallee, L., & Lam, C. K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121373 · Cited by 32
“Induction of higher extracellular TGF-β levels can occur via mechanical overload typically in the form of hypertension, myocardial infarction, as well as ischemia/reperfusion (IR) injury [40].”
BackgroundGuo, A. H., Baliira, R. K., Skinner, M. E., Kumar, S., Andren, A. C., Zhang, L., Goldsmith, R. S., Michán, S., Davis, N. J., Maccani, M. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16506-7 · Cited by 35
“In addition to promoting fibroblast activation, TGFβ signaling also induces expression of ECM components (Col1a1, Col1a2, Fbn1, Tnc), ECM modifying genes (Timp1, Adam8, Adam15, Mmp14), TGFβ cytokines, and cell adhesion genes (Icam1, Itga3, Itgb2, Spp1) (Figure 7B) (24, 35).”
Targeting Myocardial Fibrosis—A Magic Pill in Cardiovascular Medicine?
Scridon, A., & Balan, A. I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081599 · Cited by 31
“Meanwhile, in experimental studies, a loss of TGF-β receptors reduced cardiac fibrosis [59], further supporting the importance of TGFβ signaling cascades in cardiac fibrosis.”
Shen, J., Feng, J., Wu, Z., Ou, Y., Zhang, Q., Nong, Q., Wu, Q., Li, C., Tan, X., Ye, M., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81436 · Cited by 29
“SMAD2 and SMAD3, the major downstream mediators, play a key role in the activation of fibroblasts and the pathogenesis of fibrosis [59].”
Ha, C., Bakshi, S., Brahma, M. K., Potter, L., Chang, S. F., Sun, Z., Benavides, G. A., He, L., Umbarkar, P., Zou, L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029898 · Cited by 30
NLRP1 promotes TGF-β1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts
Zong, J., Zhang, H., Li, F., Liang, K. H., Liu, J., Xu, L., & Qian, W. (2018) · Journal of Molecular Histology · doi:10.1007/s10735-018-9789-9 · Cited by 29
Reward system activation improves recovery from acute myocardial infarction
Haykin, H., Avishai, E., Krot, M., Ghiringhelli, M., Reshef, M., Abboud, Y., Melamed, S., Merom, S., Boshnak, N., Azulay‐Debby, H., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00491-3 · Cited by 28
Transcription Factor 21 Regulates Cardiac Myofibroblast Formation and Fibrosis
Johansen, A. K. Z., Kasam, R. K., Vagnozzi, R. J., Lin, S. J., Gomez‐Arroyo, J. G., Shittu, A., Bowers, S., Kuwabara, Y., Grimes, K. M., Warrick, K. A., et al. (2024) · Circulation Research · doi:10.1161/circresaha.124.325527 · Cited by 31
Self-citationFang, N., Zhang, N., Jiang, X., Yan, S. R., Wang, Z., Gao, Q., Xu, M., Mu, L., Li, X., Chen, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202500963 · Cited by 35
Zhou, Y., Ng, D. Y., Richards, M., & Wang, P. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.041 · Cited by 29
“Activation of TGF-b1 signaling is central to the development of fibrosis.(10,11) In earlier work, we demonstrated miR-101a directly targets key components in the TGF-b1 signaling pathway(34) and that miR-221 reduces postmyocardial infarction cardiac fibrosis in the infarct and in remote non-infarct zones of the left v…”
BackgroundGu, J., Qiu, M., Lü, Y., Ji, Y. R., Qian, Z.-H., & Sun, W. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153461 · Cited by 28
Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin
Burke, R. M., Dirkx, R. A., Quijada, P. J., Lighthouse, J. K., Mohan, A. M., O’Brien, M., Wojciechowski, W., Woeller, C. F., Phipps, R. P., Alexis, J. D., et al. (2021) · Circulation Research · doi:10.1161/circresaha.120.317791 · Cited by 28
Repurposing Nintedanib for Pathological Cardiac Remodeling and Dysfunction
Umbarkar, P., Singh, A. P., Tousif, S., Zhang, Q., Sethu, P., & Lal, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2021.105605 · Cited by 29
Camargo, R. O., Abual’anaz, B. M., Rattan, S. G., Filomeno, K. L., & Dixon, I. (2021) · Wound Repair and Regeneration · doi:10.1111/wrr.12947 · Cited by 30
“This data indicates that Smad2 and Smad3 carry out independent roles in TGFβ1/Smad signalling in cardiac fibroblasts.(34) After MI, myofibroblasts are chronically exposed”
MethodLi, J., Li, Z., Ouyang, X.-P., & He, P. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.701279 · Cited by 36
Modulation of Cardiac Fibrosis in and Beyond Cells
Dong, F., & Kassiri, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.750626 · Cited by 31
“In response to injury or inflammation, cardiac fibroblasts are activated and differentiated into myofibroblasts which increase synthesis and secretion of ECM proteins leading to fibrosis (Khalil et al., 2017; Fu et al., 2018; Aujla and Kassiri, 2021).”
BackgroundNovel Cardiokine GDF3 Predicts Adverse Fibrotic Remodeling After Myocardial Infarction
Masurkar, N. D., Bouvet, M., Logeart, D., Jouve, C., Dramé, F., Claude, O., Roux, M., Delacroix, C., Bergerot, D., Mercadier, J.-J., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056272 · Cited by 29
Exosomes mediated fibrogenesis in dilated cardiomyopathy through a MicroRNA pathway
Fu, X., Mishra, R., Chen, L., Arfat, M. Y., Sharma, S., Kingsbury, T. J., Gunasekaran, M., Saha, P., Hong, C. C., Yang, P., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105963 · Cited by 31
Self-citationZhou, J., Tian, G., Quan, Y., Kong, Q., Huang, F., Li, J., Wu, W.-C., Tang, Y., Zhou, Z., & Liu, X. (2023) · JCI Insight · doi:10.1172/jci.insight.160745 · Cited by 32
“The specific knockdown of Smad2/3 in activated fibroblasts can reduce the extent of cardiac fibrosis after pressure overload but cannot reverse myocardial hypertrophy and heart failure, whereas the specific knockdown of TGFBR1/2 can alleviate both cardiac fibrosis and hypertrophy (30).”
BackgroundYu, J., Zhao, X., Yan, X., Li, W., Liu, Y., Wang, J., Wang, J., Yang, Y., Hao, Y., Liang, Z., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154793 · Cited by 28
Fibroblast and Immune Cell Cross-Talk in Cardiac Fibrosis
Hara, A., & Tallquist, M. D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01877-8 · Cited by 32
Aires, A., Maestro, D., RuizdelRio, J., Palanca, A., López‐Martínez, E., Llarena, I., Geraki, K., Sánchez-Cano, C., Villar, A. V., & Cortajarena, A. L. (2020) · Chemical Science · doi:10.1039/d0sc05215a · Cited by 28
Molecular mechanisms of ovarian fibrosis
Edepli, B. G., & Yaba, A. (2025) · Molecular Human Reproduction · doi:10.1093/molehr/gaaf058 · Cited by 29
“Consequently, this heteromeric complex is transported to the nucleus, where it regulates the expression of fibrosis-related genes (Nakao et al. , 1997; Xu et al. , 2016; Khalil et al. , 2017).”
Shang, L., Yue, W., Wang, D., Weng, X., Hall, M. E., Xu, Y., Hou, M., & Chen, Y. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.07.008 · Cited by 30
Deletion of Smad3 protects against diabetic myocardiopathy in db/db mice
Dong, L., Li, J., Hu, Z., Huang, X., Wang, L., Wang, H., Ronald, C. W., Lan, H. Y., & Yang, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16464 · Cited by 27
Resveratrol and Cardiac Fibrosis Prevention and Treatment
Zivarpour, P., Reiner, Ž., Hallajzadeh, J., & Mirsafaei, L. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210212125003 · Cited by 28
Exosomally derived Y RNA fragment alleviates hypertrophic cardiomyopathy in transgenic mice
Huang, F., Na, N., Ijichi, T., Wu, X., Miyamoto, K., Ciullo, A., Tran, M., Liang, L., Ibrahim, A. G.-E., Marbán, E., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.04.014 · Cited by 27
“24 June 2021 that the JNK and Smad pathways figure prominently in hypertrophyand fibrosis-related signaling.(13,14)”
BackgroundLi, Z., Wang, Q., Hu, H., Zheng, W., & Gao, C. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac1d3c · Cited by 30
Tissue Reactions and Mechanism in Cardiovascular Diseases Induced by Radiation
Liu, X., & Zhou, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314786 · Cited by 34
Liu, X., Zhao, L., Gao, Y., Chen, Y., Tian, Q., Son, J. S., Chae, S. A., de Avila, J. M., Zhu, M. J., & Du, . (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13150 · Cited by 28
“TGF-β (transforming growth factor-β) is a master regulator of tissue fibrosis.(26) The canonical pathway, TGF-β/SMADs, triggers the transcription of several profibrotic genes, including Atat2, collagen I and tissue inhibitor of matrix metalloproteinases (TIMP).”
BackgroundThe E3 ubiquitin ligases regulate inflammation in cardiovascular diseases
Chen, X., Ma, J., Wang, Z. P., & Wang, Z. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.02.008 · Cited by 30
AAV9-mediated Rbm24 overexpression induces fibrosis in the mouse heart
van den Hoogenhof, M. M. G., van der Made, I., de Groot, N. E., Damanafshan, A., van Amersfoorth, S. C. M., Zentilin, L., Giacca, M., Pinto, Y. M., & Creemers, E. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-29552-x · Cited by 29
Follistatin‐like 1: A dual regulator that promotes cardiomyocyte proliferation and fibrosis
Hu, S., Liu, H., Hu, Z., Li, L., & Yang, Y. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29588 · Cited by 28
“The TGF‐β/Smad signaling pathway mediates TGF‐β1‐induced cardiac fibroblasts to myofibroblasts by regulating Smad2/3 activation, which will lead to myocardial fibrosis (Khalil et al., 2017).”
Background
Metadata
- Authors
- Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., Karch, J., & Molkentin, J. D.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Molkentin, Jeffery D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-09-11
- Volume
- 127
- Issue
- 10
- Pages
- 3770-3783
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5617658
- OpenAlex
- W2750808153
- Cited by
- 905
- References
- 64
- Citations by year
- 2026: 92 · 2025: 102 · 2024: 128 · 2023: 121 · 2022: 144 · 2021: 110 · 2020: 84 · 2019: 85 · 2018: 34 · 2017: 2
- FWCI
- 43.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Civil War Book Review (submittedVersion)
- Language arts journal of Michigan (submittedVersion)
- Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (158486, 148429)
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01HL069779, R01HL105924)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR060636)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, TGF-beta signaling, Smad2, Smad3, cardiac fibroblasts, myofibroblasts, TGF-beta receptor, pressure overload, cardiac hypertrophy, extracellular matrix remodeling
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type I, Receptor, Transforming Growth Factor-beta Type II, Animals, Fibrosis, Heart Diseases, Male, Mice, Transgenic, Myocardium, Organ Specificity, Signal Transduction, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Gene Deletion, Receptors, Transforming Growth Factor beta, Myocytes, Cardiac, Mice, Smad2 Protein, Smad3 Protein, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.